Grant: Operating Grant: Joint Programme on Neurodegenerative Disease Research (JPND)
McGill University
$349,569.00
Stratification of presymptomatic amyotrophic lateral sclerosis: the development of novel imaging biomarkers. Jean-Francois Pradat - STRATALS
EF 2019-20
Résumé
Amyotrophic lateral sclerosis (ALS), also known as Charcot's disease, is a severe neurodegenerative disease occurring between the ages of 50 and 70 years. It causes progressive paralysis of the limbs as well as muscles of speech and swallowing. There is no effective treatment and death occurs by respiratory failure after 3 to 5 years. Thus, there is an urgent need to develop new treatments, a limit being the extreme variability of the disease in its causes (there are hereditary and non-familial forms) and its clinical presentations. It is thus essential to characterize these different forms, in order to propose a personalized treatment. Importantly, a pre-symptomatic period is now well characterized in individuals who carry a mutation responsible for familial forms of ALS, and who have not yet developed the disease. Recent developments in gene therapy, which are currently evaluated in symptomatic patients, open for the first time the possibility to prevent the disease. To achieve this goal, we need to develop new tools that will allow us to characterize this pre-symptomatic phase and to monitor the effect of these new therapies as well. For example, new imaging methods with magnetic resonance imaging now offers the possibility of knowing when the first lesions begin and how they evolve over time. In this study, we plan to develop new imaging tools and outcome metrics that will allow even finer analysis of the changes occurring in the nervous system, especially in the spinal cord, which is the main site of abnormalities. We will apply these methods to individuals carrying a mutation causing ALS, whether they are pre-symptomatic or symptomatic, and will monitor their evolution over time. Thanks to this project we will be able to better predict the evolution of this devastating disease, and to design the clinical trials with drugs under development for future therapies
Programme
Operating Grant: Joint Programme on Neurodegenerative Disease Research (JPND)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
407482
Name
Doyon Julien
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Health Research Board (Dublin, Ireland); Medical Research Council (UK); The French National Research Agency (France)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Stratification of presymptomatic amyotrophic lateral sclerosis: the development of novel imaging biomarkers. Jean-Francois Pradat - STRATALS
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$349,569
Cihrequipment2
$0
Programname2
Operating Grant: Joint Programme on Neurodegenerative Disease Research (JPND)
Keyworddelim
Brain; Brain-Spinal Cord Connectivity; Electrophysiology; Functional Imaging; Spinal Cord; Structural Imaging; Tms
Abstract
Amyotrophic lateral sclerosis (ALS), also known as Charcot's disease, is a severe neurodegenerative disease occurring between the ages of 50 and 70 years. It causes progressive paralysis of the limbs as well as muscles of speech and swallowing. There is no effective treatment and death occurs by respiratory failure after 3 to 5 years. Thus, there is an urgent need to develop new treatments, a limit being the extreme variability of the disease in its causes (there are hereditary and non-familial forms) and its clinical presentations. It is thus essential to characterize these different forms, in order to propose a personalized treatment. Importantly, a pre-symptomatic period is now well characterized in individuals who carry a mutation responsible for familial forms of ALS, and who have not yet developed the disease. Recent developments in gene therapy, which are currently evaluated in symptomatic patients, open for the first time the possibility to prevent the disease. To achieve this goal, we need to develop new tools that will allow us to characterize this pre-symptomatic phase and to monitor the effect of these new therapies as well. For example, new imaging methods with magnetic resonance imaging now offers the possibility of knowing when the first lesions begin and how they evolve over time. In this study, we plan to develop new imaging tools and outcome metrics that will allow even finer analysis of the changes occurring in the nervous system, especially in the spinal cord, which is the main site of abnormalities. We will apply these methods to individuals carrying a mutation causing ALS, whether they are pre-symptomatic or symptomatic, and will monitor their evolution over time. Thanks to this project we will be able to better predict the evolution of this devastating disease, and to design the clinical trials with drugs under development for future therapies
Competitiondate
201906
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Doyon, Julien
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Aging~ $349,569~ $0~